AGAVE-201, Phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety, and intolerability of axatilimab at 3 different doses in patients with chronic active relapsed or refractory graft-versus-host disease
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: SYNDAX PHARMACEUTICALS, INC.
- Phase: II
- Execution start: 05/05/2021
- End of execution: 30/08/2023
- PI: MANUEL JURADO CHACON